Mirum Pharmaceuticals
MIRM
117 hedge funds and large institutions have $833M invested in Mirum Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 11 closing their positions.
12,221% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $84K
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
28% more capital invested
Capital invested by funds: $650M → $833M (+$183M)
13% more funds holding
Funds holding: 104 → 117 (+13)
0.95% more ownership
Funds ownership: 90.42% → 91.37% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$18.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$13.7M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$8.15M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$5.9M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.4M |
| 2 |
BlackRock
New York
|
-$9.73M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.41M |
| 4 |
Citigroup
New York
|
-$2.24M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
126
Sandia Investment Management
Boston,
Massachusetts
| – | -$42.9K | -2,200 | Closed |
|
127
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$351 | -18 | Closed |
|
MIRM Hedge Fund Activity: Q1 2023 in Review
117 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2023, worth a combined $833M — up 28% from $650M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MIRM positions and 11 closed out — a net gain of 13 holders — while 40 added to existing stakes and 29 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $18.3M. The largest seller was State Street, cutting an estimated $13.4M.
- 117 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2023, up from 104 in Q4 2022.
- Funds reported $833M of Mirum Pharmaceuticals stock for Q1 2023, up 28% quarter-over-quarter.
- 24 funds opened new Mirum Pharmaceuticals positions in Q1 2023 and 11 closed out, a net change of +13 holders.
- The largest Mirum Pharmaceuticals buyer in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $18.3M added.
- The largest Mirum Pharmaceuticals seller in Q1 2023 was State Street, an estimated $13.4M sold.
Based on aggregated 13F filings for Q1 2023.